chongqing zhifei biological products' 23-valent pneumonia vaccine joins the "price reduction group" just one year after its launch.
①Chongqing Zhifei Biological Products' 23-valent pneumococcal polysaccharide vaccine has been reduced by nearly 30% in the listing price in provinces such as Jiangsu and jilin; ②Currently, the pneumococcal vaccine market in China is showing a competitive situation of fierce competition between overseas MNCs and domestic enterprises, while more and more companies are entering this field; ③Industry experts believe that in order to gain market share, companies can only choose to actively reduce prices.
The batch issuance of the quadrivalent HPV vaccine has dramatically decreased, and chongqing zhifei biological products' revenue and net profit have both declined. Interpretation of the financial report.
① Chongqing Zhifei Biological Products reported a decrease in revenue and net income for the first half of the year due to a decline in sales of its main product. ② The batch issuance of Merck's quadrivalent HPV vaccine, which the company represents, decreased by over 90% year-on-year. ③ As the development of domestically-produced nine-valent HPV vaccine accelerates, the company's pressure will further increase.
Core business revenue and gross margin both declined, with Apichope Pharmaceutical's net profit in the first half of the year significantly reduced. Interpreting financial reports.
Due to changes in the external market environment and internal business adjustments, apichope pharmaceutical's H1 revenue and net profit have both declined. Previously, the company was punished by the Medical Insurance Bureau due to false labeling, not only resulting in the return of a large amount of funds, but also the suspension of its qualification to participate in national procurement for 6 months.
Intense market competition combined with inventory reduction, Shenzhen Kangtai Biological Products' performance in the first half of the year has significantly declined | Interpretation of financial reports
①Affected by market competition and factors such as inventory reduction, the total revenue and net income attributable to the mother of shenzhen kangtai biological products declined in H1. ②The sales revenue of the business sector with the largest revenue contribution of the company decreased by more than 30% year-on-year. ③The accounts receivable of shenzhen kangtai biological products continued to climb, with a substantial decrease in cash flow.
Shenzhen Salubris Pharmaceuticals' H1 revenue increased by 20%, but net profit growth declined. The launch of two new drugs is facing negotiations with the government.|Interpretations of the financial report
1. In the first half of this year, the revenue of Shenzhen Salubris Pharmaceuticals increased by over 20%, but the net profit attributable to the parent only realized a growth of less than 2%; 2. During the reporting period, Shenzhen Salubris Pharmaceuticals had two innovative products approved for listing, and both products have now passed the national preliminary review this year; 3. Shenzhen Salubris Pharmaceuticals has 4 new drugs currently under market approval, including three chemical drugs and one biological drug.
Lepu Medical Technology's performance continued to decline in the first half of the year. It is expected that the revenue of the formulated business will further decrease. | Interpretations
① lepu medical technology once again submitted a half-year report with a decline in performance, and the revenue of the company's three major business sectors decreased year-on-year. ② Due to reasons such as the aging of product pipelines, lepu medical technology determines that the revenue of the formulation business sector may decrease to around 1.5 billion-1.6 billion yuan. ③ The company conducted self-inspection and rectification in response to the issues and requirements raised in the administrative supervision and regulation measures decision issued by the Beijing Securities Regulatory Bureau.